Vitanova Biomedical

What Vitanova Biomedical does

Vitanova Biomedical is an early-stage, pre-clinical biotechnology company headquartered in San Antonio, Texas, founded in 2015 to commercialize Light-Activated Intracellular Acidosis (LAIA) technology developed by founder Dr. Matthew Gdovin over a 21-year research career at the University of Texas at San Antonio. The company's core product, LUXVIVO, is a nanoparticle-based cancer therapy in which proprietary upconverting nanoparticles are injected intratumorally and activated by deep-penetrating laser light to induce cancer-specific intracellular acidosis and trigger cell death, while preserving surrounding healthy tissue. The platform combines three mechanistic principles: intracellular acidosis as a cytotoxic mechanism, light-activatable compounds, and antibody/antigen-conjugated nanoparticles for tumor targeting. Preclinical efficacy has been demonstrated across mouse, equine, feline, and canine tumor models, with a pilot equine melanoma study reporting complete regression within 14 days after a single 5-minute treatment and a 40% reduction in untreated lesions via an adaptive immune response.

The company is executing a veterinary-first regulatory strategy. It has secured Minor Use/Major Species (MUMS) designation from the FDA Center for Veterinary Medicine for canine melanoma, canine hemangiosarcoma, and canine osteosarcoma, and has an active Investigational New Animal Drug Application (INAD) for canine melanoma. The intended go-to-market upon conditional FDA approval is direct sales to veterinary oncology specialists, veterinary clinics, and animal hospitals, with companion animal cancer patients as the primary segment and human oncology as a future expansion target. To date, Vitanova has been funded almost entirely through small non-dilutive grants, including an NSF SBIR seed award in August 2020, and remains pre-revenue with 1–10 employees. An AI-assisted treatment model is being developed to compute laser parameters based on tissue composition, but currently functions as an optimization adjunct rather than a core commercial differentiator.

The leadership team is founder-controlled: Dr. Gdovin serves as CEO, CSO, and Founder; Greg Espenhover as CFO and Co-Founder; and Tom Roberts, formerly in senior leadership at Acelity and Hoffmann-La Roche, as Chairman of the Board. The company's IP base rests on a granted patent covering the non-invasive light-activated cancer cell killing method and the peer-reviewed introduction of LAIA in Seminars in Cancer Biology (2017).

Name

Vitanova Biomedical

Legal name

Vitanova Biomedical

Website

https://vitanovabiomedical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Vitanova Biomedical is a pre-clinical biotechnology company developing LUXVIVO, a light-activated intracellular acidosis (LAIA) nanoparticle cancer therapy. It is pursuing FDA Center for Veterinary Medicine approval for canine melanoma, hemangiosarcoma, and osteosarcoma as a veterinary-first pathway to human oncology.

Ownership category

akta.pro rank

Headquarters

HQ city

Kerrville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. LUXVIVO Veterinary Cancer Therapy: Pre-commercial stage. Once FDA conditional approval is obtained for veterinary applications (canine melanoma, hemangiosarcoma, osteosarcoma), the company will commercialize LUXVIVO as a treatment for companion animals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Vitanova Biomedical is developing LUXVIVO, a proprietary combination cancer therapy platform based on its Light-Activated Intracellular Acidosis (LAIA) technology. The therapy combines intratumorally injected proprietary upconverting nanoparticles with deep-penetrating laser activation to induce cancer-specific intracellular acidosis, triggering cancer cell death without damaging healthy tissue. The company is pursuing FDA Center for Veterinary Medicine (CVM) approval first, with MUMS designation granted and an INAD file opened for canine melanoma, before advancing to human oncology applications.

Product overview

Vitanova Biomedical offers LUXVIVO, a proprietary nanoparticle-based cancer therapy platform that utilizes Light-Activated Intracellular Acidosis (LAIA) technology. The platform combines laser activation of proprietary upconverting nanoparticles with precision targeting via antibody/antigen conjugation to induce cancer cell death through intracellular acidosis. The company is pursuing FDA Center for Veterinary Medicine approval first, with MUMS designation and INAD file established for canine melanoma, before advancing to human oncology applications.

Differentiator

Problem solved

Functional benefit

Brands

• LUXVIVO: Proprietary laser-activated nanoparticle cancer therapy product being developed for FDA approval to treat canine melanoma, canine hemangiosarcoma, canine osteosarcoma, and equine melanoma.

Products and services

• LUXVIVO

Quantifiable outcome

• Complete regression of melanoma tumors in horses within 14 days with single 5-minute laser treatment
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Nanospectra Biosciences: Houston-based clinical-stage biotech developing AuroLase, a laser-activated gold nanoshell therapy for prostate cancer and other solid tumors. Closest mechanistic peer to Vitanova's LAIA — both rely on intratumorally injected nanoparticles activated by external light to destroy cancer cells while sparing healthy tissue.
• Torigen Pharmaceuticals: Veterinary oncology company offering VetiVax, an autologous tumor vaccine for companion animals with cancer. Most directly comparable as a small, early-stage company pursuing FDA-approved novel cancer therapies specifically for the companion animal oncology market.
• ELIAS Animal Health: Veterinary immuno-oncology company with a personalized adoptive cell therapy for dogs with osteosarcoma, one of the same MUMS-designated indications Vitanova is targeting. Direct peer in both veterinary oncology and novel-mechanism cancer treatment for companion animals.

Broad incumbents

• Zoetis: Largest global animal health company, marketing Palladia (toceranib) — the leading FDA-approved canine cancer therapy. Represents the dominant incumbent commercial channel and reimbursement benchmark Vitanova would face in the companion animal oncology market upon approval.
• Virbac: Global animal health company with oncology and specialty products for companion animals. Comparable as an established veterinary pharma player whose distribution, regulatory, and sales infrastructure would be a logical commercialization partner or acquirer for Vitanova.
• Dechra Pharmaceuticals: UK-based veterinary specialty pharmaceutical company focused on companion animal therapeutics including oncology. Comparable as a mid-sized specialty player with oncology exposure that could serve as a strategic exit pathway for a veterinary-first biotech.
• Phibro Animal Health: Diversified animal health and nutrition company with companion animal pharmaceutical products. Comparable as an established commercial-stage animal health company that competes for share of veterinary oncology prescribing.

Emerging players

• Nanobiotix: Clinical-stage French biotech developing NBTXR3, a hafnium oxide nanoparticle radioenhancer for multiple solid tumor indications. Highly comparable mechanism (nanoparticle-based cancer therapy) but a much larger, publicly listed company pursuing human oncology directly.
• CytImmune Sciences: Clinical-stage biotech developing tumor-targeted gold nanoparticle delivery platforms for cancer therapy. Comparable as a nanoparticle-engineering oncology platform company at a similar development stage and scale as Vitanova.

Others

• PetDx: Veterinary molecular diagnostics company offering liquid biopsy cancer detection for dogs. Adjacent rather than competitive — operates in companion animal oncology but in diagnostics rather than therapeutics, making it a complementary peer for ecosystem mapping.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/vitanovabiomedical
• Facebookfacebook.com/vnbinc
• LinkedInlinkedin.com/company/vitanova-biomedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitanova Biomedical